| 001 | 305513 | ||
| 005 | 20251203120135.0 | ||
| 024 | 7 | _ | |a 10.1002/hed.70070 |2 doi |
| 024 | 7 | _ | |a pmid:41122870 |2 pmid |
| 024 | 7 | _ | |a 1043-3074 |2 ISSN |
| 024 | 7 | _ | |a 0148-6403 |2 ISSN |
| 024 | 7 | _ | |a 1097-0347 |2 ISSN |
| 024 | 7 | _ | |a 1930-2398 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-02197 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Han, Rui |0 0009-0004-8843-9938 |b 0 |
| 245 | _ | _ | |a Loss of the Y Chromosome in Oral Potentially Premalignant Disorders Predicts Malignant Progression: An Integrative Cross-Species Multi-Cohort Bioinformatic Study. |
| 260 | _ | _ | |a New York, NY [u.a.] |c 2025 |b Wiley Interscience |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1764759660_1331671 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #LA:E220# / #DKFZ-MOST-Ca204# / epub |
| 520 | _ | _ | |a The loss of the Y chromosome (LOY) and the extreme down-regulation of Y chromosome gene expression (EDY) are frequently observed in oral squamous cell carcinoma (OSCC). However, their roles in oral potentially malignant disorders (OPMDs) are unclear.A comprehensive bioinformatic analysis was performed using publicly available datasets from chemically induced mouse OSCC models and human cohorts. The analysis included LOY/EDY detection, gene set variation analysis (GSVA), PROGENy pathway profiling, cell-to-cell communication inference, and epigenetic correlation studies.LOY was prevalent among men with OPMD, and EDY was identified in both mouse models and human OPMDs. The presence of LOY/EDY was associated with a higher risk of OPMD progression to OSCC. Single-cell analysis revealed that EDY-positive epithelial cells exhibited elevated oncogenic pathway activity and enhanced IL17-IL17RC signaling, possibly due to the loss of KDM5D in epithelial cells and altered epigenetic regulation.LOY/EDY can be detected in OPMD and promotes malignant progression by altering oncogenic signaling and epithelial cell interactions. LOY/EDY may serve as both a diagnostic biomarker and a therapeutic target, improving clinical management and patient outcomes. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a extreme downâregulation of Y chromosome gene expression (EDY) |2 Other |
| 650 | _ | 7 | |a loss of the Y chromosome (LOY) |2 Other |
| 650 | _ | 7 | |a lysine demethylase 5D (KDM5D) |2 Other |
| 650 | _ | 7 | |a oral potentially premalignant disorders (OPMD) |2 Other |
| 650 | _ | 7 | |a oral squamous cell carcinoma (OSCC) |2 Other |
| 700 | 1 | _ | |a Poell, Jos B |b 1 |
| 700 | 1 | _ | |a Conde-Lopez, Cristina |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Salo, Tuula |b 3 |
| 700 | 1 | _ | |a Kurth, Ina |0 P:(DE-He78)f3723bca6eb95009d4c95a7590617b68 |b 4 |u dkfz |
| 700 | 1 | _ | |a Brakenhoff, Ruud H |b 5 |
| 700 | 1 | _ | |a Hess, Jochen |0 P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f |b 6 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1002/hed.70070 |g p. hed.70070 |0 PERI:(DE-600)2001440-5 |p nn |t Head & neck |v nn |y 2025 |x 1043-3074 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:305513 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)f3723bca6eb95009d4c95a7590617b68 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-18 |w ger |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2024-12-18 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-18 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-18 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b HEAD NECK-J SCI SPEC : 2022 |d 2024-12-18 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-18 |
| 920 | 2 | _ | |0 I:(DE-He78)E220-20160331 |k E220 |l E220 Radioonkologie Radiobiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E220-20160331 |k E220 |l E220 Radioonkologie Radiobiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E220-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::